Merck & Co Still Plans to buy Cubist, Despite Patent Setback

11.12.2014 - Merck & Co has said it will proceed with its planned $8.4 billion acquisition of Cubist Pharmaceuticals in the first quarter of 2015 and still expects the deal to boost its long...